Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients
14 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy
OncoAlert and ecancer weekly round up for August 2 - August 14, 2021
Targeted therapy for breast cancer
Oncogenesis: Lung cancer
Triple negative breast cancer: OlympiA study
Pancreatic and Hepatobiliary Cancers
Immunotherapy in lung cancer
Oesophageal and gastric cancers
BEACON-CRC: first-line bevacizumab in colorectal cancer treatment
Patterns of recurrence after a radical nephroureterectomy in high-risk upper tract urothelial carcinoma
Part 1: When to test